Floatz logo

Olaparib

Breast Carcinoma

The Netherlands Cancer InstituteSmall moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

208 Active assets in the Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
Trastuzumab Deruxtecan
SWOG Cancer Research Network
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Pertuzumab
SWOG Cancer Research Network
Phase 3BBB

View all 50 →

Same molecule, other indications

Olaparib is also rated in:

fallopian tube serous adenocarcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
ovarian carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →
hereditary breast ovarian cancer syndromeActive
BB
Indicative · Phase 3
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →